Price Disclosure Reductions for 2016 October Cycle
Page last updated: 9 September 2016
This summary of 1 October 2016 price disclosure reductions for the 2016 October Cycle only includes medicines taking a price disclosure reduction. The price disclosure legal determination mentioned at the bottom of this page includes brands where a weighted average disclosed price is determined but there will not be a price disclosure reduction (see Schedule 2 of the determination).
The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 1960 (the Regulations).
The outcomes below show percentage (%) price differences and ex-manufacturer level prices. They do not include fees and mark-ups. Details about later publication of other prices are set out below.
2015 Price Disclosure Changes
The 2015 Access and Sustainability package introduced the following amendments to price disclosure arrangements:
- Flow-on Reductions for F2 Combination Items;
- No Reduction Items – Low Volume / Low Discount; and
- Removal of Originator Brand Data from Weighted Adjusted Disclosed Price (WADP) calculations in certain circumstances.
The 2016 October Cycle is the first price disclosure cycle to incorporate the ‘Removal of Originator Brand Data’ measure and the second cycle to incorporate the ‘Flow-on Reductions for F2 Combination Items’ and the ‘No Reduction Items – Low Volume / Low Discount’ measures. Further information regarding these changes can be found on the 2015 Price Disclosure Changes - Fact Sheet.
Flow-on Reductions for F2 Combination Items
Responsible persons with a brand of an F2 combination item should understand that:
- if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 October 2016 if the price of a component ingredient will be reduced on 1 October 2016, and flowing this reduced component price on to the combination item will result in a lower price than the direct reduction;
- if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction; or
- there will be a back-capture reduction day for any outstanding F2 combination items on 1 October 2016. This means that any F2 combination item with no component drug price reduction on 1 April 2016, or 1 October 2016, will have a back-capture calculation done for the 1 October 2016 reduction day. The back-capture calculation will work out whether flowing on the F2 component drug price from the most recent price disclosure reduction (if any reduction has occurred) would result in a lower price than the current price for the combination item. If so, the flow-on reduction will be applied on 1 October 2016.
Calculations are currently being completed for flow-on price disclosure reductions to F2 combination items. Outcomes will be communicated to responsible persons with brands of affected drugs. Letters will set out the new prices for F2 combination items and seek PB11a forms. F2 combination item pricing will require attention by affected companies during mid to late July 2016.
Legal Determination & Next Steps
The weighted average disclosed prices for each brand, including brands with a determination but no reduction, are in the legal determination on the legislation.gov.au website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their April 2016 PBS approved ex-manufacturer price and the weighted average disclosed price for the 2016 October Cycle was below 10%. Any new brands of an existing pharmaceutical item with a determination in Schedule 1 that listed after 31 March 2016 will also take the reduction on 1 October 2016 under section 99ADHA of the Act.
An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes was 5 pm AEST on 25 July 2016.
Indicative prices for 1 October 2016 (including price to pharmacy, Dispensed Price for Maximum Quantity and price premiums) were published on 28 July 2016. Subscribe to PBS News to receive notice when they become available.
Final prices for 1 October 2016 (including all price to pharmacy, Dispensed Price for Maximum Quantity/Amount and price premiums) will be available from early September 2016.
| Legal Instrument Drug (drugs marked with an * have a pharmaceutical item/s that met the 'no reduction' criteria) |
Legal Instrument MoA | Legal Instrument Form | Average AEMP ($) |
WAPD (%) across a drug/MoA |
WADP - potential October '16 PBS Price (AEMP) ($) per pharmaceutical item |
April '16 AEMP ($) |
Percentage difference between April '16 and October '16 PBS prices (AEMP) (%) per pharmaceutical item |
Calculations based on: O = all brand data G = originator brand data removed |
|---|---|---|---|---|---|---|---|---|
| [Average AEMP minus WAPD = WADP] | [Difference between April ‘16 AEMP & WADP = % Difference] | |||||||
|
Aciclovir |
Oral |
Tablet 200 mg |
8.30 |
14.09% |
7.13 |
8.30 |
14.10% |
OWAPD |
|
Aciclovir |
Oral |
Tablet 800 mg |
36.15 |
14.09% |
31.06 |
36.15 |
14.08% |
OWAPD |
|
Acitretin |
Oral |
Capsule 10 mg |
124.32 |
10.96% |
110.69 |
124.32 |
10.96% |
OWAPD |
|
Acitretin |
Oral |
Capsule 25 mg |
252.83 |
10.96% |
225.12 |
252.83 |
10.96% |
OWAPD |
|
Alendronic acid |
Oral |
Tablet 70 mg (as alendronate sodium) |
4.56 |
10.95% |
4.06 |
4.56 |
10.96% |
OWAPD |
|
Alendronic acid with colecalciferol |
Oral |
Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol |
26.91 |
51.75% |
12.98 |
26.91 |
51.77% |
OWAPD |
|
Alendronic acid with colecalciferol |
Oral |
Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol |
26.91 |
51.75% |
12.98 |
26.91 |
51.77% |
OWAPD |
|
Alendronic acid with colecalciferol and calcium |
Oral |
Pack containing 4 tablets containing alendronic acid 70 mg (as alendronate sodium) with 140 micrograms colecalciferol and 48 tablets calcium 500 mg (as carbonate) |
31.85 |
38.99% |
19.43 |
27.50 |
29.35% |
OWAPD |
|
Amisulpride |
Oral |
Tablet 100 mg |
10.07 |
24.09% |
7.64 |
8.56 |
10.75% |
GWAPD |
|
Amisulpride |
Oral |
Tablet 200 mg |
43.35 |
24.09% |
32.91 |
36.86 |
10.72% |
GWAPD |
|
Amisulpride |
Oral |
Tablet 400 mg |
78.61 |
24.09% |
59.67 |
66.85 |
10.74% |
GWAPD |
|
Anastrozole |
Oral |
Tablet 1 mg |
55.73 |
54.77% |
25.21 |
49.16 |
48.72% |
GWAPD |
|
Atorvastatin |
Oral |
Tablet 10 mg (as calcium) |
2.78 |
40.50% |
1.65 |
2.37 |
30.38% |
GWAPD |
|
Atorvastatin |
Oral |
Tablet 20 mg (as calcium) |
4.10 |
40.50% |
2.44 |
3.49 |
30.09% |
GWAPD |
|
Atorvastatin |
Oral |
Tablet 40 mg (as calcium) |
5.77 |
40.50% |
3.43 |
4.92 |
30.28% |
GWAPD |
|
Atorvastatin |
Oral |
Tablet 80 mg (as calcium) |
8.25 |
40.50% |
4.91 |
7.03 |
30.16% |
GWAPD |
|
Bicalutamide |
Oral |
Tablet 50 mg |
81.83 |
36.40% |
52.04 |
70.32 |
26.00% |
GWAPD |
|
Bisoprolol |
Oral |
Tablet containing bisoprolol fumarate 10 mg |
18.68 |
30.34% |
13.01 |
16.63 |
21.77% |
GWAPD |
|
Bisoprolol |
Oral |
Tablet containing bisoprolol fumarate 2.5 mg |
11.96 |
30.34% |
8.33 |
10.64 |
21.71% |
GWAPD |
|
Bisoprolol |
Oral |
Tablet containing bisoprolol fumarate 5 mg |
14.94 |
30.34% |
10.41 |
13.30 |
21.73% |
GWAPD |
|
Bleomycin |
Injection |
Powder for injection containing bleomycin sulfate 15,000 I.U. |
88.13 |
55.30% |
39.39 |
88.13 |
55.30% |
OWAPD |
|
Candesartan |
Oral |
Tablet containing candesartan cilexetil 16 mg |
7.85 |
30.91% |
5.42 |
6.58 |
17.63% |
OWAPD |
|
Candesartan |
Oral |
Tablet containing candesartan cilexetil 32 mg |
9.49 |
30.91% |
6.56 |
7.95 |
17.48% |
OWAPD |
|
Candesartan |
Oral |
Tablet containing candesartan cilexetil 4 mg |
0.88 |
30.91% |
0.61 |
0.74 |
17.57% |
OWAPD |
|
Candesartan |
Oral |
Tablet containing candesartan cilexetil 8 mg |
2.62 |
30.91% |
1.81 |
2.20 |
17.73% |
OWAPD |
|
Candesartan with hydrochlorothiazide |
Oral |
Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg |
8.96 |
29.79% |
6.29 |
8.09 |
22.25% |
OWAPD |
|
Candesartan with hydrochlorothiazide |
Oral |
Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg |
10.66 |
29.79% |
7.48 |
9.46 |
20.93% |
OWAPD |
|
Candesartan with hydrochlorothiazide |
Oral |
Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg |
11.47 |
29.79% |
8.05 |
10.97 |
26.62% |
OWAPD |
|
Capecitabine |
Oral |
Tablet 150 mg |
40.04 |
47.82% |
20.89 |
30.70 |
31.95% |
OWAPD |
|
Capecitabine |
Oral |
Tablet 500 mg |
248.19 |
47.82% |
129.51 |
190.30 |
31.94% |
OWAPD |
|
Captopril |
Oral |
Tablet 12.5 mg |
4.30 |
16.53% |
3.59 |
4.30 |
16.51% |
GWAPD |
|
Captopril |
Oral |
Tablet 25 mg |
6.22 |
16.53% |
5.19 |
6.22 |
16.56% |
GWAPD |
|
Captopril |
Oral |
Tablet 50 mg |
12.27 |
16.53% |
10.24 |
12.27 |
16.54% |
GWAPD |
|
Cefalotin |
Injection |
Powder for injection 1 g (as sodium) |
21.19 |
36.48% |
13.46 |
26.71 |
49.61% |
OWAPD |
|
Celecoxib |
Oral |
Capsule 100 mg |
17.59 |
46.44% |
9.42 |
10.80 |
12.78% |
OWAPD |
|
Celecoxib |
Oral |
Capsule 200 mg |
17.59 |
46.44% |
9.42 |
10.80 |
12.78% |
OWAPD |
|
Citalopram |
Oral |
Tablet 10 mg (as hydrobromide) |
1.06 |
15.08% |
0.90 |
1.06 |
15.09% |
GWAPD |
|
Citalopram |
Oral |
Tablet 20 mg (as hydrobromide) |
1.60 |
15.08% |
1.36 |
1.60 |
15.00% |
GWAPD |
|
Citalopram |
Oral |
Tablet 40 mg (as hydrobromide) |
2.71 |
15.08% |
2.30 |
2.71 |
15.13% |
GWAPD |
|
Clomipramine |
Oral |
Tablet containing clomipramine hydrochloride 25 mg |
6.25 |
11.61% |
5.52 |
6.25 |
11.68% |
GWAPD |
|
Clopidogrel |
Oral |
Tablet 75 mg |
7.23 |
38.27% |
4.46 |
5.54 |
19.49% |
GWAPD |
|
Clopidogrel |
Oral |
Tablet 75 mg (as besilate) |
7.23 |
38.27% |
4.46 |
5.54 |
19.49% |
GWAPD |
|
Clopidogrel |
Oral |
Tablet 75 mg (as hydrogen sulfate) |
7.23 |
38.27% |
4.46 |
5.54 |
19.49% |
GWAPD |
|
Cyclosporin |
Oral |
Capsule 100 mg |
162.77 |
16.08% |
136.60 |
162.77 |
16.08% |
GWAPD |
|
Cyclosporin |
Oral |
Capsule 25 mg |
38.39 |
16.08% |
32.22 |
38.39 |
16.07% |
GWAPD |
|
Cyclosporin |
Oral |
Capsule 50 mg |
79.88 |
16.08% |
67.04 |
79.88 |
16.07% |
GWAPD |
|
Cyproterone |
Oral |
Tablet containing cyproterone acetate 100 mg |
66.25 |
12.42% |
58.02 |
66.25 |
12.42% |
GWAPD |
|
Cyproterone |
Oral |
Tablet containing cyproterone acetate 50 mg |
17.01 |
12.42% |
14.90 |
17.01 |
12.40% |
GWAPD |
|
Desferrioxamine |
Injection |
Powder for injection containing desferrioxamine mesylate 2 g |
28.74 |
22.01% |
22.41 |
28.74 |
22.03% |
OWAPD |
|
Desferrioxamine |
Injection |
Powder for injection containing desferrioxamine mesylate 500 mg |
136.39 |
22.01% |
106.37 |
168.66 |
36.93% |
OWAPD |
|
Diltiazem |
Oral |
Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg |
6.99 |
10.60% |
6.25 |
6.99 |
10.59% |
GWAPD |
|
Diltiazem |
Oral |
Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg |
9.45 |
10.60% |
8.45 |
9.45 |
10.58% |
GWAPD |
|
Diltiazem |
Oral |
Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg |
12.39 |
10.60% |
11.08 |
12.39 |
10.57% |
GWAPD |
|
Diltiazem |
Oral |
Tablet containing diltiazem hydrochloride 60 mg |
6.31 |
10.60% |
5.64 |
6.31 |
10.62% |
GWAPD |
|
Donepezil |
Oral |
Tablet containing donepezil hydrochloride 10 mg |
17.59 |
34.88% |
11.45 |
17.59 |
34.91% |
GWAPD |
|
Donepezil |
Oral |
Tablet containing donepezil hydrochloride 5 mg |
17.59 |
34.88% |
11.45 |
17.59 |
34.91% |
GWAPD |
|
Dorzolamide with timolol |
Application to the eye |
Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL |
14.10 |
14.31% |
12.08 |
14.10 |
14.33% |
OWAPD |
|
Doxorubicin - pegylated liposomal |
Injection |
Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL |
425.24 |
27.79% |
307.07 |
425.24 |
27.79% |
OWAPD |
|
Doxorubicin - pegylated liposomal |
Injection |
Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL |
1,012.48 |
27.79% |
731.11 |
1,012.48 |
27.79% |
OWAPD |
|
Duloxetine |
Oral |
Capsule 30 mg (as hydrochloride) |
7.47 |
38.18% |
4.62 |
6.08 |
24.01% |
GWAPD |
|
Duloxetine |
Oral |
Capsule 60 mg (as hydrochloride) |
10.67 |
38.18% |
6.60 |
8.67 |
23.88% |
GWAPD |
|
Enalapril |
Oral |
Tablet containing enalapril maleate 10 mg |
3.74 |
14.10% |
3.21 |
3.74 |
14.17% |
OWAPD |
|
Enalapril |
Oral |
Tablet containing enalapril maleate 20 mg |
4.76 |
14.10% |
4.09 |
4.76 |
14.08% |
OWAPD |
|
Enalapril |
Oral |
Tablet containing enalapril maleate 5 mg |
2.27 |
14.10% |
1.95 |
2.27 |
14.10% |
OWAPD |
|
Enalapril with hydrochlorothiazide |
Oral |
Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg |
15.02 |
33.09% |
10.05 |
15.02 |
33.09% |
GWAPD |
|
Escitalopram |
Oral |
Tablet 10 mg (as oxalate) |
3.40 |
30.74% |
2.35 |
2.73 |
13.92% |
GWAPD |
|
Escitalopram |
Oral |
Tablet 20 mg (as oxalate) |
3.43 |
30.74% |
2.38 |
2.75 |
13.45% |
GWAPD |
|
Exemestane |
Oral |
Tablet 25 mg |
84.64 |
31.17% |
58.26 |
71.67 |
18.71% |
GWAPD |
|
Famciclovir |
Oral |
Tablet 125 mg |
36.22 |
31.53% |
24.80 |
31.37 |
20.94% |
GWAPD |
|
Famciclovir |
Oral |
Tablet 250 mg |
36.22 |
31.53% |
24.80 |
31.37 |
20.94% |
GWAPD |
|
Famciclovir |
Oral |
Tablet 500 mg |
54.33 |
31.53% |
37.20 |
47.06 |
20.95% |
GWAPD |
|
Fentanyl |
Transdermal |
Transdermal patch 1.28 mg |
12.73 |
29.79% |
8.94 |
10.68 |
16.29% |
GWAPD |
|
Fentanyl |
Transdermal |
Transdermal patch 10.20 mg |
50.59 |
29.79% |
35.52 |
42.46 |
16.34% |
GWAPD |
|
Fentanyl |
Transdermal |
Transdermal patch 12.375 mg |
40.77 |
29.79% |
28.62 |
34.21 |
16.34% |
GWAPD |
|
Fentanyl |
Transdermal |
Transdermal patch 12.6 mg |
40.77 |
29.79% |
28.62 |
34.21 |
16.34% |
GWAPD |
|
Fentanyl |
Transdermal |
Transdermal patch 16.5 mg |
50.59 |
29.79% |
35.52 |
42.46 |
16.34% |
GWAPD |
|
Fentanyl |
Transdermal |
Transdermal patch 16.8 mg |
50.59 |
29.79% |
35.52 |
42.46 |
16.34% |
GWAPD |
|
Fentanyl |
Transdermal |
Transdermal patch 2.063 mg |
12.73 |
29.79% |
8.94 |
10.68 |
16.29% |
GWAPD |
|
Fentanyl |
Transdermal |
Transdermal patch 2.1 mg |
12.73 |
29.79% |
8.94 |
10.68 |
16.29% |
GWAPD |
|
Fentanyl |
Transdermal |
Transdermal patch 2.55 mg |
16.19 |
29.79% |
11.37 |
13.59 |
16.34% |
GWAPD |
|
Fentanyl |
Transdermal |
Transdermal patch 4.125 mg |
16.19 |
29.79% |
11.37 |
13.59 |
16.34% |
GWAPD |
|
Fentanyl |
Transdermal |
Transdermal patch 4.2 mg |
16.19 |
29.79% |
11.37 |
13.59 |
16.34% |
GWAPD |
|
Fentanyl |
Transdermal |
Transdermal patch 5.10 mg |
29.75 |
29.79% |
20.89 |
24.97 |
16.34% |
GWAPD |
|
Fentanyl |
Transdermal |
Transdermal patch 7.65 mg |
40.77 |
29.79% |
28.62 |
34.21 |
16.34% |
GWAPD |
|
Fentanyl |
Transdermal |
Transdermal patch 8.25 mg |
29.75 |
29.79% |
20.89 |
24.97 |
16.34% |
GWAPD |
|
Fentanyl |
Transdermal |
Transdermal patch 8.4 mg |
29.75 |
29.79% |
20.89 |
24.97 |
16.34% |
GWAPD |
|
Filgrastim |
Injection |
Injection 120 micrograms in 0.2 mL single use pre-filled syringe (Nivestim) |
330.09 |
29.81% |
231.69 |
330.09 |
29.81% |
OWAPD |
|
Filgrastim |
Injection |
Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Neupogen) |
825.22 |
29.81% |
579.22 |
825.22 |
29.81% |
OWAPD |
|
Filgrastim |
Injection |
Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Nivestim) |
825.22 |
29.81% |
579.22 |
825.22 |
29.81% |
OWAPD |
|
Filgrastim |
Injection |
Injection 300 micrograms in 0.5 mL single use pre-filled syringe (TevaGrastim) |
825.22 |
29.81% |
579.22 |
825.22 |
29.81% |
OWAPD |
|
Filgrastim |
Injection |
Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Zarzio) |
412.61 |
29.81% |
289.61 |
412.61 |
29.81% |
OWAPD |
|
Filgrastim |
Injection |
Injection 300 micrograms in 1 mL |
825.22 |
29.81% |
579.22 |
825.22 |
29.81% |
OWAPD |
|
Filgrastim |
Injection |
Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Neupogen) |
1,322.88 |
29.81% |
928.53 |
1,322.88 |
29.81% |
OWAPD |
|
Filgrastim |
Injection |
Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Nivestim) |
1,322.88 |
29.81% |
928.53 |
1,322.88 |
29.81% |
OWAPD |
|
Filgrastim |
Injection |
Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Zarzio) |
661.44 |
29.81% |
464.26 |
661.44 |
29.81% |
OWAPD |
|
Filgrastim |
Injection |
Injection 480 micrograms in 0.8 mL single use pre-filled syringe (TevaGrastim) |
1,322.88 |
29.81% |
928.53 |
1,322.88 |
29.81% |
OWAPD |
|
Filgrastim |
Injection |
Injection 480 micrograms in 1.6 mL |
1,322.88 |
29.81% |
928.53 |
1,322.88 |
29.81% |
OWAPD |
|
Flucloxacillin |
Injection |
Powder for injection 1 g (as sodium) |
8.84 |
44.05% |
4.95 |
11.17 |
55.68% |
OWAPD |
|
Flucloxacillin |
Injection |
Power for injection 500 g (as sodium) |
2.66 |
44.05% |
1.49 |
2.66 |
43.98% |
OWAPD |
|
Fluconazole |
Oral |
Capsule 100 mg |
26.30 |
12.13% |
23.11 |
26.30 |
12.13% |
GWAPD |
|
Fluconazole |
Oral |
Capsule 200 mg |
51.23 |
12.13% |
45.02 |
51.23 |
12.12% |
GWAPD |
|
Fluconazole |
Oral |
Capsule 50 mg |
13.51 |
12.13% |
11.87 |
13.51 |
12.14% |
GWAPD |
|
Fluorouracil |
Injection |
Injection 1000 mg in 20 mL |
9.23 |
30.29% |
6.43 |
9.23 |
30.34% |
OWAPD |
|
Fluorouracil |
Injection |
Injection 2500 mg in 50 mL |
23.08 |
30.29% |
16.09 |
23.08 |
30.29% |
OWAPD |
|
Fluorouracil |
Injection |
Injection 500 mg in 10 mL |
23.08 |
30.29% |
16.09 |
23.08 |
30.29% |
OWAPD |
|
Fluorouracil |
Injection |
Injection 5000 mg in 100 mL |
46.16 |
30.29% |
32.18 |
46.16 |
30.29% |
OWAPD |
|
Fluvoxamine |
Oral |
Tablet containing fluvoxamine maleate 100 mg |
9.05 |
11.89% |
7.97 |
9.05 |
11.93% |
GWAPD |
|
Fluvoxamine |
Oral |
Tablet containing fluvoxamine maleate 50 mg |
5.97 |
11.89% |
5.26 |
5.97 |
11.89% |
GWAPD |
|
Fosinopril |
Oral |
Tablet containing fosinopril sodium 10 mg |
4.95 |
15.64% |
4.18 |
4.95 |
15.56% |
GWAPD |
|
Fosinopril |
Oral |
Tablet containing fosinopril sodium 20 mg |
7.40 |
15.64% |
6.24 |
7.40 |
15.68% |
GWAPD |
|
Fosinopril with hydrochlorothiazide |
Oral |
Tablet containing fosinopril sodium 10 mg with hydrochlorothiazide 12.5 mg |
12.05 |
31.40% |
8.27 |
12.05 |
31.37% |
GWAPD |
|
Fosinopril with hydrochlorothiazide |
Oral |
Tablet containing fosinopril sodium 20 mg with hydrochlorothiazide 12.5 mg |
17.70 |
31.40% |
12.14 |
17.70 |
31.41% |
GWAPD |
|
Galantamine |
Oral |
Capsule (prolonged release) 16 mg (as hydrobromide) |
32.09 |
11.19% |
28.50 |
32.09 |
11.19% |
GWAPD |
|
Galantamine |
Oral |
Capsule (prolonged release) 24 mg (as hydrobromide) |
38.24 |
11.19% |
33.96 |
38.24 |
11.19% |
GWAPD |
|
Galantamine |
Oral |
Capsule (prolonged release) 8 mg (as hydrobromide) |
26.24 |
11.19% |
23.30 |
26.24 |
11.20% |
GWAPD |
|
Glimepiride |
Oral |
Tablet 1 mg |
1.02 |
11.57% |
0.90 |
1.02 |
11.76% |
GWAPD |
|
Glimepiride |
Oral |
Tablet 2 mg |
1.95 |
11.57% |
1.72 |
1.95 |
11.79% |
GWAPD |
|
Glimepiride |
Oral |
Tablet 3 mg |
2.48 |
11.57% |
2.19 |
2.48 |
11.69% |
GWAPD |
|
Glimepiride |
Oral |
Tablet 4 mg |
3.05 |
11.57% |
2.70 |
3.05 |
11.48% |
GWAPD |
|
Granisetron |
Injection |
Concentrated injection 3 mg (as hydrochloride) in 3 mL |
2.93 |
17.41% |
2.42 |
2.93 |
17.41% |
GWAPD |
|
Granisetron |
Oral |
Tablet 2 mg (as hydrochloride) |
9.29 |
10.76% |
8.29 |
9.29 |
10.76% |
OWAPD |
|
Hydroxychloroquine |
Oral |
Tablet containing hydroxychloroquine sulfate 200 mg |
18.99 |
21.91% |
14.83 |
18.99 |
21.91% |
GWAPD |
|
Imiquimod |
Application |
Cream 50 mg per g, 2 g, 2 |
83.11 |
15.47% |
70.25 |
83.11 |
15.47% |
OWAPD |
|
Imiquimod |
Application |
Cream 50 mg per g, 250 mg single use sachets, 12 |
83.11 |
15.47% |
70.25 |
83.11 |
15.47% |
OWAPD |
|
Indapamide |
Oral |
Tablet containing indapamide hemihydrate 1.5 mg (sustained release) |
10.42 |
22.29% |
8.10 |
10.42 |
22.26% |
GWAPD |
|
Indapamide |
Oral |
Tablet containing indapamide hemihydrate 2.5 mg |
7.14 |
22.29% |
5.55 |
7.14 |
22.27% |
GWAPD |
|
Irbesartan |
Oral |
Tablet 150 mg |
3.25 |
41.25% |
1.91 |
2.80 |
31.79% |
GWAPD |
|
Irbesartan |
Oral |
Tablet 300 mg |
6.50 |
41.25% |
3.82 |
5.58 |
31.54% |
GWAPD |
|
Irbesartan |
Oral |
Tablet 75 mg |
2.28 |
41.25% |
1.34 |
1.96 |
31.63% |
GWAPD |
|
Irbesartan with hydrochlorothiazide |
Oral |
Tablet 150 mg-12.5 mg |
3.98 |
44.99% |
2.19 |
3.98 |
44.97% |
GWAPD |
|
Irbesartan with hydrochlorothiazide |
Oral |
Tablet 300 mg-12.5 mg |
7.31 |
44.99% |
4.02 |
7.09 |
43.30% |
GWAPD |
|
Irbesartan with hydrochlorothiazide |
Oral |
Tablet 300 mg-25 mg |
7.96 |
44.99% |
4.38 |
7.96 |
44.97% |
GWAPD |
|
Isotretinoin |
Oral |
Capsule 10 mg |
24.79 |
11.18% |
22.02 |
24.79 |
11.17% |
GWAPD |
|
Isotretinoin |
Oral |
Capsule 20 mg |
38.64 |
11.18% |
34.32 |
38.64 |
11.18% |
GWAPD |
|
Isotretinoin |
Oral |
Capsule 40 mg |
34.88 |
11.18% |
30.98 |
34.88 |
11.18% |
GWAPD |
|
Lamivudine* |
Oral |
Tablet 100 mg |
81.22 |
31.87% |
55.34 |
63.74 |
13.18% |
GWAPD |
|
Lamivudine* |
Oral |
Tablet 150 mg |
153.34 |
31.87% |
104.47 |
120.34 |
13.19% |
GWAPD |
|
Lamivudine* |
Oral |
Tablet 300 mg |
153.34 |
31.87% |
104.47 |
120.34 |
13.19% |
GWAPD |
|
Lansoprazole |
Oral |
Capsule 15 mg |
5.81 |
34.87% |
3.78 |
4.92 |
23.17% |
GWAPD |
|
Lansoprazole |
Oral |
Capsule 30 mg |
9.70 |
34.87% |
6.32 |
8.22 |
23.11% |
GWAPD |
|
Lansoprazole |
Oral |
Tablet 15 mg (orally disintegrating) |
5.40 |
34.87% |
3.52 |
4.57 |
22.98% |
GWAPD |
|
Lansoprazole |
Oral |
Tablet 30 mg (orally disintegrating) |
9.70 |
34.87% |
6.32 |
8.22 |
23.11% |
GWAPD |
|
Latanoprost |
Application to the eye |
Eye drops 50 micrograms per mL, 2.5 mL |
13.99 |
50.86% |
6.87 |
11.57 |
40.62% |
GWAPD |
|
Leflunomide |
Oral |
Tablet 10 mg |
35.04 |
31.52% |
24.00 |
30.38 |
21.00% |
GWAPD |
|
Leflunomide |
Oral |
Tablet 20 mg |
53.37 |
31.52% |
36.55 |
46.25 |
20.97% |
GWAPD |
|
Lercanidipine |
Oral |
Tablet containing lercanidipine hydrochloride 10 mg |
2.47 |
12.13% |
2.17 |
2.47 |
12.15% |
GWAPD |
|
Lercanidipine |
Oral |
Tablet containing lercanidipine hydrochloride 20 mg |
4.12 |
12.13% |
3.62 |
4.12 |
12.14% |
GWAPD |
|
Letrozole |
Oral |
Tablet 2.5 mg |
47.88 |
50.29% |
23.80 |
42.39 |
43.85% |
GWAPD |
|
Levetiracetam* |
Oral |
Tablet 1 g |
58.57 |
41.51% |
34.26 |
48.42 |
29.24% |
GWAPD |
|
Levetiracetam* |
Oral |
Tablet 250 mg |
21.09 |
41.51% |
12.34 |
17.44 |
29.24% |
GWAPD |
|
Levetiracetam* |
Oral |
Tablet 500 mg |
35.15 |
41.51% |
20.56 |
29.06 |
29.25% |
GWAPD |
|
Levonorgestrel with ethinyloestradiol* |
Oral |
Pack containing 21 tablets 100 micrograms-20 micrograms and 7 inert tablets |
7.18 |
11.05% |
6.39 |
7.18 |
11.00% |
GWAPD |
|
Levonorgestrel with ethinyloestradiol* |
Oral |
Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets |
7.18 |
11.05% |
6.39 |
7.18 |
11.00% |
GWAPD |
|
Macrogol 3350 |
Oral |
Oral liquid 13.125 g in 25 mL with electrolytes, 500 mL |
6.37 |
26.30% |
4.69 |
6.37 |
26.37% |
GWAPD |
|
Macrogol 3350 |
Oral |
Powder for oral solution 510 g |
9.55 |
26.30% |
7.04 |
9.55 |
26.28% |
GWAPD |
|
Macrogol 3350 |
Oral |
Sachets containing powder for oral solution 13.125 g with electrolytes, 30 |
9.55 |
26.30% |
7.04 |
9.55 |
26.28% |
GWAPD |
|
Macrogol 3350 |
Oral |
Sachets containing powder for oral solution 17 g, 30 |
9.55 |
26.30% |
7.04 |
9.55 |
26.28% |
GWAPD |
|
Memantine |
Oral |
Tablet containing memantine hydrochloride 10 mg |
43.71 |
21.22% |
34.43 |
43.71 |
21.23% |
GWAPD |
|
Memantine |
Oral |
Tablet containing memantine hydrochloride 20 mg |
43.71 |
21.22% |
34.43 |
43.71 |
21.23% |
GWAPD |
|
Metformin |
Oral |
Tablet (extended release) containing metformin hydrochloride 1 g |
4.47 |
10.26% |
4.01 |
4.47 |
10.29% |
GWAPD |
|
Metformin |
Oral |
Tablet (extended release) containing metformin hydrochloride 500 mg |
4.47 |
10.26% |
4.01 |
4.47 |
10.29% |
GWAPD |
|
Metformin |
Oral |
Tablet containing metformin hydrochloride 1 g |
4.86 |
10.26% |
4.36 |
4.86 |
10.29% |
GWAPD |
|
Metformin |
Oral |
Tablet containing metformin hydrochloride 500 mg |
2.79 |
10.26% |
2.50 |
2.79 |
10.39% |
GWAPD |
|
Metformin |
Oral |
Tablet containing metformin hydrochloride 850 mg |
2.79 |
10.26% |
2.50 |
2.79 |
10.39% |
GWAPD |
|
Methotrexate |
Injection |
Injection 5 mg in 2 mL vial |
29.66 |
44.52% |
16.46 |
39.17 |
57.98% |
OWAPD |
|
Methotrexate |
Injection |
Injection 50 mg in 2 mL vial |
5.64 |
44.52% |
3.13 |
7.42 |
57.82% |
OWAPD |
|
Methotrexate |
Injection |
Solution concentrate for I.V. infusion 1000 mg in 10 mL vial |
41.66 |
44.52% |
23.11 |
41.66 |
44.53% |
OWAPD |
|
Methotrexate |
Injection |
Solution concentrate for I.V. infusion 500 mg in 20 mL vial |
56.41 |
44.52% |
31.30 |
74.20 |
57.82% |
OWAPD |
|
Methotrexate |
Injection |
Solution concentrate for I.V. infusion 5000 mg in 50 mL vial |
208.27 |
44.52% |
115.55 |
208.27 |
44.52% |
OWAPD |
|
Metoprolol |
Oral |
Tablet containing metoprolol tartrate 100 mg |
2.52 |
10.47% |
2.26 |
2.52 |
10.32% |
GWAPD |
|
Metoprolol |
Oral |
Tablet containing metoprolol tartrate 50 mg |
1.98 |
10.47% |
1.77 |
1.98 |
10.61% |
GWAPD |
|
Montelukast |
Oral |
Tablet, chewable, 4 mg (as sodium) |
12.39 |
31.43% |
8.50 |
12.39 |
31.40% |
OWAPD |
|
Montelukast |
Oral |
Tablet, chewable, 5 mg (as sodium) |
11.65 |
31.43% |
7.99 |
11.65 |
31.42% |
OWAPD |
|
Mycophenolic acid* |
Oral |
Capsule containing mycophenolate mofetil 250 mg |
35.75 |
28.31% |
25.63 |
35.75 |
28.31% |
GWAPD |
|
Mycophenolic acid* |
Oral |
Tablet containing mycophenolate mofetil 500 mg |
71.48 |
28.31% |
51.24 |
71.48 |
28.32% |
GWAPD |
|
Norfloxacin |
Oral |
Tablet 400 mg |
3.74 |
11.06% |
3.33 |
3.74 |
10.96% |
OWAPD |
|
Olanzapine |
Oral |
Tablet 10 mg |
25.21 |
46.21% |
13.56 |
19.15 |
29.19% |
GWAPD |
|
Olanzapine |
Oral |
Tablet 10 mg (as benzoate) |
25.21 |
46.21% |
13.56 |
19.15 |
29.19% |
GWAPD |
|
Olanzapine |
Oral |
Tablet 10 mg (orally disintegrating) |
25.21 |
46.21% |
13.56 |
19.15 |
29.19% |
GWAPD |
|
Olanzapine |
Oral |
Tablet 15 mg (orally disintegrating) |
37.81 |
46.21% |
20.34 |
28.71 |
29.15% |
GWAPD |
|
Olanzapine |
Oral |
Tablet 2.5 mg |
6.30 |
46.21% |
3.39 |
4.79 |
29.23% |
GWAPD |
|
Olanzapine |
Oral |
Tablet 2.5 mg (as benzoate) |
6.30 |
46.21% |
3.39 |
4.79 |
29.23% |
GWAPD |
|
Olanzapine |
Oral |
Tablet 20 mg (orally disintegrating) |
50.42 |
46.21% |
27.12 |
38.28 |
29.15% |
GWAPD |
|
Olanzapine |
Oral |
Tablet 5 mg |
12.48 |
46.21% |
6.71 |
9.48 |
29.22% |
GWAPD |
|
Olanzapine |
Oral |
Tablet 5 mg (as benzoate) |
12.48 |
46.21% |
6.71 |
9.48 |
29.22% |
GWAPD |
|
Olanzapine |
Oral |
Tablet 5 mg (orally disintegrating) |
12.48 |
46.21% |
6.71 |
9.48 |
29.22% |
GWAPD |
|
Olanzapine |
Oral |
Tablet 7.5 mg |
18.91 |
46.21% |
10.17 |
14.36 |
29.18% |
GWAPD |
|
Olanzapine |
Oral |
Tablet 7.5 mg (as benzoate) |
18.91 |
46.21% |
10.17 |
14.36 |
29.18% |
GWAPD |
|
Olanzapine |
Oral |
Wafer 10 mg |
25.21 |
46.21% |
13.56 |
19.15 |
29.19% |
GWAPD |
|
Olanzapine |
Oral |
Wafer 15 mg |
37.81 |
46.21% |
20.34 |
28.71 |
29.15% |
GWAPD |
|
Olanzapine |
Oral |
Wafer 20 mg |
50.42 |
46.21% |
27.12 |
38.28 |
29.15% |
GWAPD |
|
Olanzapine |
Oral |
Wafer 5 mg |
12.48 |
46.21% |
6.71 |
9.48 |
29.22% |
GWAPD |
|
Ondansetron |
Oral |
Tablet (orally disintegrating) 4 mg |
5.54 |
24.71% |
4.17 |
5.54 |
24.73% |
GWAPD |
|
Ondansetron |
Oral |
Tablet (orally disintegrating) 8 mg |
8.68 |
24.71% |
6.54 |
8.68 |
24.65% |
GWAPD |
|
Ondansetron |
Oral |
Tablet 4 mg (as hydrochloride dihydrate) |
5.54 |
24.71% |
4.17 |
5.54 |
24.73% |
GWAPD |
|
Ondansetron |
Oral |
Tablet 8 mg (as hydrochloride dihydrate) |
8.68 |
24.71% |
6.54 |
8.68 |
24.65% |
GWAPD |
|
Ondansetron |
Oral |
Wafer 4 mg |
5.54 |
24.71% |
4.17 |
5.54 |
24.73% |
GWAPD |
|
Ondansetron |
Oral |
Wafer 8 mg |
8.68 |
24.71% |
6.54 |
8.68 |
24.65% |
GWAPD |
|
Oxybutynin |
Oral |
Tablet containing oxybutynin hydrochloride 5 mg |
5.69 |
27.42% |
4.13 |
5.69 |
27.42% |
GWAPD |
|
Paclitaxel |
Injection |
Solution concentrate for I.V. infusion 100 mg in 16.7 mL |
31.16 |
46.88% |
16.55 |
31.16 |
46.89% |
OWAPD |
|
Paclitaxel |
Injection |
Solution concentrate for I.V. infusion 150 mg in 25 mL |
46.75 |
46.88% |
24.83 |
46.75 |
46.89% |
OWAPD |
|
Paclitaxel |
Injection |
Solution concentrate for I.V. infusion 30 mg in 5 mL |
9.35 |
46.88% |
4.97 |
9.35 |
46.84% |
OWAPD |
|
Paclitaxel |
Injection |
Solution concentrate for I.V. infusion 300 mg in 50 mL |
93.49 |
46.88% |
49.66 |
93.49 |
46.88% |
OWAPD |
|
Pantoprazole |
Oral |
Tablet (enteric coated) 20 mg (as sodium sesquihydrate) |
1.88 |
26.75% |
1.38 |
1.58 |
12.66% |
GWAPD |
|
Pantoprazole |
Oral |
Tablet (enteric coated) 40 mg (as sodium sesquihydrate) |
3.87 |
26.75% |
2.83 |
3.25 |
12.92% |
GWAPD |
|
Paroxetine |
Oral |
Tablet 20 mg (as hydrochloride) |
4.59 |
17.96% |
3.77 |
4.59 |
17.86% |
GWAPD |
|
Paroxetine |
Oral |
Tablet 20 mg (as mesilate) |
4.59 |
17.96% |
3.77 |
4.59 |
17.86% |
GWAPD |
|
Perindopril |
Oral |
Tablet containing perindopril arginine 10 mg |
6.66 |
27.24% |
4.85 |
5.85 |
17.09% |
GWAPD |
|
Perindopril |
Oral |
Tablet containing perindopril arginine 2.5 mg |
2.33 |
27.24% |
1.70 |
2.05 |
17.07% |
GWAPD |
|
Perindopril |
Oral |
Tablet containing perindopril arginine 5 mg |
4.35 |
27.24% |
3.17 |
3.82 |
17.02% |
GWAPD |
|
Perindopril |
Oral |
Tablet containing perindopril erbumine 2 mg |
2.33 |
27.24% |
1.70 |
2.05 |
17.07% |
GWAPD |
|
Perindopril |
Oral |
Tablet containing perindopril erbumine 4 mg |
4.35 |
27.24% |
3.17 |
3.82 |
17.02% |
GWAPD |
|
Perindopril |
Oral |
Tablet containing perindopril erbumine 8 mg |
6.66 |
27.24% |
4.85 |
5.85 |
17.09% |
GWAPD |
|
Pioglitazone |
Oral |
Tablet 15 mg (as hydrochloride) |
14.64 |
39.63% |
8.84 |
11.97 |
26.15% |
GWAPD |
|
Pioglitazone |
Oral |
Tablet 30 mg (as hydrochloride) |
22.52 |
39.63% |
13.60 |
18.41 |
26.13% |
GWAPD |
|
Pioglitazone |
Oral |
Tablet 45 mg (as hydrochloride) |
29.28 |
39.63% |
17.68 |
23.93 |
26.12% |
GWAPD |
|
Prochlorperazine |
Oral |
Tablet containing prochlorperazine maleate 5 mg |
1.15 |
11.85% |
1.01 |
1.15 |
12.17% |
GWAPD |
|
Quetiapine* |
Oral |
Tablet (modified release) 150 mg (as fumarate) |
34.85 |
33.45% |
23.19 |
30.65 |
24.34% |
GWAPD |
|
Quetiapine* |
Oral |
Tablet (modified release) 200 mg (as fumarate) |
47.49 |
33.45% |
31.60 |
41.76 |
24.33% |
GWAPD |
|
Quetiapine* |
Oral |
Tablet (modified release) 50 mg (as fumarate) |
24.63 |
33.45% |
16.39 |
21.66 |
24.33% |
GWAPD |
|
Quetiapine* |
Oral |
Tablet 100 mg (as fumarate) |
34.85 |
33.45% |
23.19 |
30.65 |
24.34% |
GWAPD |
|
Quetiapine* |
Oral |
Tablet 200 mg (as fumarate) |
47.49 |
33.45% |
31.60 |
41.76 |
24.33% |
GWAPD |
|
Quetiapine* |
Oral |
Tablet 25 mg (as fumarate) |
12.31 |
33.45% |
8.19 |
10.83 |
24.38% |
GWAPD |
|
Quetiapine* |
Oral |
Tablet 300 mg (as fumarate) |
69.67 |
33.45% |
46.37 |
61.27 |
24.32% |
GWAPD |
|
Rabeprazole |
Oral |
Tablet containing rabeprazole sodium 10 mg (enteric coated) |
5.88 |
39.00% |
3.59 |
4.94 |
27.33% |
GWAPD |
|
Rabeprazole |
Oral |
Tablet containing rabeprazole sodium 20 mg (enteric coated) |
5.88 |
39.00% |
3.59 |
4.94 |
27.33% |
GWAPD |
|
Ramipril |
Oral |
Capsule 1.25 mg |
1.22 |
12.63% |
1.07 |
1.22 |
12.30% |
GWAPD |
|
Ramipril |
Oral |
Capsule 10 mg |
3.94 |
12.63% |
3.44 |
3.94 |
12.69% |
GWAPD |
|
Ramipril |
Oral |
Capsule 2.5 mg |
1.78 |
12.63% |
1.56 |
1.78 |
12.36% |
GWAPD |
|
Ramipril |
Oral |
Capsule 5 mg |
2.23 |
12.63% |
1.95 |
2.23 |
12.56% |
GWAPD |
|
Ramipril |
Oral |
Tablet 1.25 mg |
1.22 |
12.63% |
1.07 |
1.22 |
12.30% |
GWAPD |
|
Ramipril |
Oral |
Tablet 10 mg |
3.94 |
12.63% |
3.44 |
3.94 |
12.69% |
GWAPD |
|
Ramipril |
Oral |
Tablet 2.5 mg |
1.78 |
12.63% |
1.56 |
1.78 |
12.36% |
GWAPD |
|
Ramipril |
Oral |
Tablet 5 mg |
2.23 |
12.63% |
1.95 |
2.23 |
12.56% |
GWAPD |
|
Riluzole |
Oral |
Tablet 50 mg |
321.02 |
33.78% |
212.58 |
268.73 |
20.89% |
GWAPD |
|
Risedronic acid |
Oral |
Tablet (enteric coated) containing risedronate sodium 35 mg |
25.40 |
12.07% |
22.33 |
25.40 |
12.09% |
GWAPD |
|
Risedronic acid |
Oral |
Tablet containing risedronate sodium 150 mg |
27.53 |
12.07% |
24.21 |
27.53 |
12.06% |
GWAPD |
|
Risedronic acid |
Oral |
Tablet containing risedronate sodium 30 mg |
173.47 |
12.07% |
152.53 |
173.47 |
12.07% |
GWAPD |
|
Risedronic acid |
Oral |
Tablet containing risedronate sodium 35 mg |
25.40 |
12.07% |
22.33 |
25.40 |
12.09% |
GWAPD |
|
Risedronic acid |
Oral |
Tablet containing risedronate sodium 5 mg |
25.40 |
12.07% |
22.33 |
25.40 |
12.09% |
GWAPD |
|
Risperidone |
Oral |
Tablet 1 mg |
9.08 |
20.46% |
7.22 |
9.08 |
20.48% |
GWAPD |
|
Risperidone |
Oral |
Tablet 2 mg |
20.77 |
20.46% |
16.52 |
20.77 |
20.46% |
GWAPD |
|
Risperidone |
Oral |
Tablet 3 mg |
32.02 |
20.46% |
25.47 |
32.02 |
20.46% |
GWAPD |
|
Risperidone |
Oral |
Tablet 4 mg |
43.23 |
20.46% |
34.39 |
43.23 |
20.45% |
GWAPD |
|
Rosuvastatin |
Oral |
Tablet 10 mg (as calcium) |
12.32 |
35.47% |
7.95 |
10.07 |
21.05% |
OWAPD |
|
Rosuvastatin |
Oral |
Tablet 20 mg (as calcium) |
17.54 |
35.47% |
11.32 |
14.33 |
21.00% |
OWAPD |
|
Rosuvastatin |
Oral |
Tablet 40 mg (as calcium) |
25.01 |
35.47% |
16.14 |
20.44 |
21.04% |
OWAPD |
|
Rosuvastatin |
Oral |
Tablet 5 mg (as calcium) |
8.39 |
35.47% |
5.41 |
6.86 |
21.14% |
OWAPD |
|
Sildenafil |
Oral |
Tablet 20 mg (as citrate) |
574.01 |
28.49% |
410.47 |
514.77 |
20.26% |
OWAPD |
|
Simvastatin |
Oral |
Tablet 10 mg |
1.38 |
15.47% |
1.17 |
1.38 |
15.22% |
GWAPD |
|
Simvastatin |
Oral |
Tablet 20 mg |
2.00 |
15.47% |
1.69 |
2.00 |
15.50% |
GWAPD |
|
Simvastatin |
Oral |
Tablet 40 mg |
2.87 |
15.47% |
2.43 |
2.87 |
15.33% |
GWAPD |
|
Simvastatin |
Oral |
Tablet 5 mg |
1.00 |
15.47% |
0.85 |
1.00 |
15.00% |
GWAPD |
|
Simvastatin |
Oral |
Tablet 80 mg |
4.12 |
15.47% |
3.48 |
4.12 |
15.53% |
GWAPD |
|
Sorbitol with sodium citrate and sodium lauryl sulfoacetate |
Rectal |
Enemas 3.125 g-450 mg-45 mg in 5 mL, 12 |
10.45 |
18.76% |
8.49 |
10.45 |
18.76% |
GWAPD |
|
Sumatriptan |
Oral |
Tablet (fast disintegrating) 50 mg (as succinate) |
3.22 |
16.60% |
2.69 |
3.22 |
16.46% |
GWAPD |
|
Sumatriptan |
Oral |
Tablet 50 mg (as succinate) |
3.22 |
16.60% |
2.69 |
3.22 |
16.46% |
GWAPD |
|
Tamoxifen |
Oral |
Tablet 10 mg (as citrate) |
12.15 |
14.60% |
10.21 |
12.15 |
15.97% |
GWAPD |
|
Tamoxifen |
Oral |
Tablet 20 mg (as citrate) |
10.53 |
16.00% |
8.85 |
10.53 |
15.95% |
GWAPD |
|
Telmisartan |
Oral |
Tablet 40 mg |
3.75 |
33.34% |
2.50 |
3.34 |
25.15% |
OWAPD |
|
Telmisartan |
Oral |
Tablet 80 mg |
10.86 |
33.34% |
7.24 |
9.67 |
25.13% |
OWAPD |
|
Telmisartan with hydrochlorothiazide |
Oral |
Tablet 40 mg-12.5 mg |
5.25 |
30.15% |
3.67 |
4.45 |
17.53% |
OWAPD |
|
Telmisartan with hydrochlorothiazide |
Oral |
Tablet 80 mg-12.5 mg |
13.12 |
30.15% |
9.16 |
11.08 |
17.33% |
OWAPD |
|
Telmisartan with hydrochlorothiazide |
Oral |
Tablet 80 mg-25 mg |
14.23 |
30.15% |
9.94 |
12.07 |
17.65% |
OWAPD |
|
Temozolomide |
Oral |
Capsule 100 mg |
236.41 |
34.38% |
155.13 |
236.41 |
34.38% |
GWAPD |
|
Temozolomide |
Oral |
Capsule 140 mg |
326.03 |
34.38% |
213.94 |
326.03 |
34.38% |
GWAPD |
|
Temozolomide |
Oral |
Capsule 180 mg |
394.80 |
34.38% |
259.07 |
394.80 |
34.38% |
GWAPD |
|
Temozolomide |
Oral |
Capsule 20 mg |
55.18 |
34.38% |
36.21 |
55.18 |
34.38% |
GWAPD |
|
Temozolomide |
Oral |
Capsule 250 mg |
561.69 |
34.38% |
368.58 |
561.69 |
34.38% |
GWAPD |
|
Temozolomide |
Oral |
Capsule 5 mg |
18.77 |
34.38% |
12.32 |
18.77 |
34.36% |
GWAPD |
|
Tirofiban |
Injection |
Solution concentrate for I.V. infusion 12.5 mg (as hydrochloride) in 50 mL |
264.60 |
12.25% |
232.19 |
264.60 |
12.25% |
OWAPD |
|
Topiramate* |
Oral |
Capsule 25 mg |
12.72 |
41.09% |
7.49 |
10.17 |
26.35% |
GWAPD |
|
Topiramate* |
Oral |
Capsule 50 mg |
21.21 |
41.09% |
12.49 |
16.96 |
26.36% |
GWAPD |
|
Topiramate* |
Oral |
Tablet 100 mg |
33.40 |
41.09% |
19.68 |
26.70 |
26.29% |
GWAPD |
|
Topiramate* |
Oral |
Tablet 200 mg |
56.12 |
41.09% |
33.06 |
44.87 |
26.32% |
GWAPD |
|
Topiramate* |
Oral |
Tablet 25 mg |
12.93 |
41.09% |
7.62 |
10.34 |
26.31% |
GWAPD |
|
Topiramate* |
Oral |
Tablet 50 mg |
21.24 |
41.09% |
12.51 |
16.98 |
26.33% |
GWAPD |
|
Tramadol |
Injection |
Injection containing tramadol hydrochloride 100 mg in 2 mL |
3.70 |
28.34% |
2.65 |
3.31 |
19.94% |
GWAPD |
|
Tropisetron |
Injection |
I.V. injection 5 mg (as hydrochloride) in 5 mL |
5.88 |
22.28% |
4.57 |
5.88 |
22.28% |
OWAPD |
|
Valaciclovir |
Oral |
Tablet 500 mg (as hydrochloride) |
10.64 |
40.17% |
6.37 |
8.40 |
24.17% |
GWAPD |
|
Valproic acid |
Oral |
Tablet (enteric coated) containing sodium valproate 200 mg |
6.40 |
14.67% |
5.46 |
6.40 |
14.69% |
GWAPD |
|
Valproic acid |
Oral |
Tablet (enteric coated) containing sodium valproate 500 mg |
12.67 |
14.67% |
10.81 |
12.67 |
14.68% |
GWAPD |
|
Venlafaxine |
Oral |
Capsule (modified release) 150 mg (as hydrochloride) |
7.80 |
38.81% |
4.77 |
6.64 |
28.16% |
GWAPD |
|
Venlafaxine |
Oral |
Capsule (modified release) 37.5 mg (as hydrochloride) |
3.62 |
38.81% |
2.22 |
3.09 |
28.16% |
GWAPD |
|
Venlafaxine |
Oral |
Capsule (modified release) 75 mg (as hydrochloride) |
6.39 |
38.81% |
3.91 |
5.45 |
28.26% |
GWAPD |
